ASSERTIO HOLDINGS Reports Q2 FY2023 Earnings Results for June 30, 2023

August 24, 2023

🌥️Earnings Overview

On August 3 2023, ASSERTIO HOLDINGS ($NASDAQ:ASRT) reported their earnings results for the second quarter of FY2023, ending June 30 2023. Compared to the same period of the previous year, total revenue had increased by 16.7% to USD 41.0 million, and net income had grown 8.2% to USD 8.5 million.

Price History

ASSERTIO HOLDINGS reported its quarterly earnings results for June 30, 2023 on Thursday, revealing a slight decline in stock prices from the previous day. The company opened at $5.3 and closed at $5.4, a decrease of 1.1% from its last closing price of $5.4. These results are in line with the company’s goal of providing consistent financial performance and delivering shareholder value. This dividend was provided in order to reward the long-term shareholders.

Overall, ASSERTIO HOLDINGS’ Q2 FY2023 earnings results demonstrate the company’s commitment to meeting its financial goals and delivering value to shareholders. The special dividend and stock repurchase plan are indicative of the company’s efforts to reward long-term shareholders and should serve to increase investor confidence. Live Quote…

About the Company

  • Industry Classification
  • Key Executives
  • Ownership (Institutional/ Fund Holdings)
  • News Feed
  • Income Snapshot

    Below shows the total revenue, net income and net margin for Assertio Holdings. More…

    Total Revenues Net Income Net Margin
    168.02 97.71 67.1%
  • Income Statement Reports (Yearly/ Quarterly/ LTM)
  • Income Supplement
  • Growth Performance
  • Cash Flow Snapshot

    Below shows the cash from operations, investing and financing for Assertio Holdings. More…

    Operations Investing Financing
    78.06 -26.96 -33.19
  • Cash Flow Statement (Yearly/ Quarterly/ LTM)
  • Cash Flow Supplement
  • Balance Sheet Snapshot

    Below shows the total assets, liabilities and book value per share for Assertio Holdings. More…

    Total Assets Total Liabilities Book Value Per Share
    405.18 150.91 4.5
  • Balance Sheet (Yearly/ Quarterly)
  • Balance Sheet Supplement
  • Key Ratios Snapshot

    Some of the financial key ratios for Assertio Holdings are shown below. More…

    3Y Rev Growth 3Y Operating Profit Growth Operating Margin
    2.5% -45.3% 14.7%
    FCF Margin ROE ROA
    46.0% 6.1% 3.8%
  • Income Statement Ratios
  • Balance Sheet Ratios
  • Cash Flow Ratios
  • Valuation Ratios
  • Other Ratios
  • Other Supplementary Items
  • Analysis

    At GoodWhale, we have extensively analyzed the financials of ASSERTIO HOLDINGS. Based on our Risk Rating, ASSERTIO HOLDINGS is classified as a high risk investment in terms of both financial and business aspects. In order to provide more information about ASSERTIO HOLDINGS’ financials, we have detected 2 risk warnings in their income sheet and balance sheet. To access further information about these risks, you can become a registered user of GoodWhale. This will enable you to see our detailed analysis of ASSERTIO HOLDING’s finances, giving you all the information you need to make an informed decision about your investment. More…

  • Risk Rating Analysis
  • Star Chart Analysis
  • Valuation Analysis

  • Peers

    The company’s products are distributed through its network of wholesalers, retailers, and distributors in the United States and internationally. Assertio Holdings Inc. is a publicly traded company on the NASDAQ Global Market under the ticker symbol ASRT. The company’s competitors include Chandra Bhagat Pharma Ltd, DHG Pharmaceutical JSC, and Yuhan Corp.

    – Chandra Bhagat Pharma Ltd ($BSE:542934)

    Chandra Bhagat Pharma Ltd is a pharmaceutical company with a market cap of 754.51M as of 2022. The company has a Return on Equity of 9.62%. The company manufactures and markets a range of pharmaceutical products, including antibiotics, anti-infectives, cardiovascular drugs, and more.

    – DHG Pharmaceutical JSC ($HOSE:DHG)

    DGH Pharmaceutical JSC is a pharmaceutical company that manufactures and sells drugs and other medical products. The company has a market cap of 10.94T as of 2022 and a return on equity of 16.55%. The company’s products include prescription and over-the-counter drugs, vitamins, and other nutritional supplements.

    – Yuhan Corp ($KOSE:000105)

    As of 2022, Yuhan Corp has a market capitalization of 3.85 trillion and a return on equity of 4.29%. The company is engaged in the development, manufacture, and sale of pharmaceutical and other health-related products.


    Investors should be encouraged by Assertio Holdings‘ second quarter earnings results for FY2023. Total revenue increased by 16.7%, while net income rose 8.2%, indicating a strong quarter for the company. These solid growth figures indicate that the company is on the right track, and investors could benefit from investing in this stock. These indicators point to a positive outlook for Assertio Holdings, making it an attractive investment opportunity.

    Recent Posts

    Leave a Comment